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Suppressing AP1 Factor Signaling in the Suprabasal
Epidermis Produces a Keratoderma Phenotype
Ellen A. Rorke1, Gautam Adhikary2, Christina A. Young2, Dennis R. Roop3 and Richard L. Eckert2,4,5
Keratodermas comprise a heterogeneous group of highly debilitating and painful disorders characterized by
thickening of the skin with marked hyperkeratosis. Some of these diseases are caused by genetic mutation,
whereas other forms are acquired in response to environmental factors. Our understanding of signaling changes
that underlie these diseases is limited. In the present study, we describe a keratoderma phenotype in mice in
response to suprabasal epidermis-specific inhibition of activator protein 1 transcription factor signaling. These
mice develop a severe phenotype characterized by hyperplasia, hyperkeratosis, parakeratosis, and impaired
epidermal barrier function. The skin is scaled, constricting bands encircle the tail and digits, the footpads are
thickened and scaled, and loricrin staining is markedly reduced in the cornified layers and increased in the
nucleus. Features of this phenotype, including nuclear loricrin localization and pseudoainhum (autoamputation),
are characteristic of the Vohwinkel syndrome. We confirm that the phenotype develops in a loricrin-null genetic
background, indicating that suppressed suprabasal AP1 factor function is sufficient to drive this disease. We also
show that the phenotype regresses when suprabasal AP1 factor signaling is restored. Our findings suggest that
suppression of AP1 factor signaling in the suprabasal epidermis is a key event in the pathogenesis of
keratoderma.
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INTRODUCTION
Keratodermas comprise a group of disorders characterized by
thickening of the epidermis with marked hyperplasia and
hyperkeratosis (Christiano, 1997). Keratodermas include both
inherited and acquired forms. Inherited forms of this disease
are associated with expression of mutant intermediate
filaments (keratins), cornified envelope–associated proteins
(loricrin, transglutaminase), cohesion proteins (desmoglein 1,
plakophilin, desmoplakin), proteins of cell-to-cell communi-
cation (connexins), and transmembrane proteins (cathepsin C)
(Christiano, 1997; Kimyai-Asadi et al., 2002; Amagai and
Stanley, 2012). Most of these mutations are autosomal
dominant, although some are recessive (Kimyai-Asadi et al.,
2002). In addition, some forms of keratoderma are acquired in
response to treatment with drugs, exposure to chemicals,
malnutrition, infection, or response to cancer (Patel et al.,
2007). The underlying biochemical changes in these diseases
are not well understood.
The Vohwinkel syndrome is a form of keratoderma char-
acterized by honeycomb-like palmoplantar keratoderma,
hyperkeratosis, prominent tissue buildup on the dorsal hands
and feet, pseudoainhum with digit amputation, and hearing
impairment (OMIM 124500) that is caused by a mutation in
the connexin 26 gene (Maestrini et al., 1999). In addition,
Camisa and Rossana reported a variant of the Vohwinkel
syndrome characterized by ichthyosiform dermatosis and no
hearing impairment (OMIM 604117) (Camisa and Rossana,
1984; Schmuth et al., 2004). This autosomal-dominant
disease, also called loricrin keratoderma or keratoderma
with ichthyosis, is caused by mutation of the loricrin gene
(Korge et al., 1997). The loricrin mutations are frameshift
changes due to a single nucleotide insertion in the loricrin-
coding sequence. The most frequent mutation is 730insG
(Korge et al., 1997; Maestrini et al., 1996; Takahashi et al.,
1999; Matsumoto et al., 2001; O’Driscoll et al., 2002;
Gedicke et al., 2006; Drera et al., 2008), although mutations
are also observed at 662insT (Armstrong et al., 1998), 709insC
(Ishida-Yamamoto et al., 1997), and c.545-546insG (Song
et al., 2008). These mutations result in synthesis of an
extended form of loricrin that includes a nuclear localization
signal. Instead of being incorporated into the cornified
envelope, the mutant loricrin translocates into the nucleus
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where it produces changes that are not well characterized
(Ishida-Yamamoto et al., 1998b, 1999, 2000).
Mouse model studies support a role for mutant loricrin in
the pathogenesis of loricrin keratoderma. Overexpression of
wild-type human loricrin in mouse epidermis shows a normal
phenotype that is associated with incorporation of human
loricrin into the murine cornified envelope (Yoneda and
Steinert, 1993). Loricrin knockout mice have also been
produced, and these mice display only a mild phenotype
(Koch et al., 2000; Jarnik et al., 2002). In contrast, transgenic
mice expressing mutant loricrin display features of loricrin
keratoderma (Suga et al., 2000), and this phenotype is more
dramatic when the mutant is expressed in the absence of wild-
type loricrin (Suga et al., 2000). The phenotype includes
nuclear localization of loricrin, hyperproliferation,
hyperkeratosis, parakeratosis, and pseudoainhum of the tail
(Suga et al., 2000). These findings argue that this is a gain-of-
function mutation and that wild-type loricrin is not necessary
for the phenotype. However, beyond the accumulation of
nuclear loricrin, subsequent events in disease progression are
not understood. Recent studies, using HaCaT cell cultures
expressing mutant loricrin, suggest that nuclear accumulation
of loricrin alters intracellular signaling and that this may
contribute to the keratoderma phenotype (Yoneda et al.,
2010a, b). These findings suggest that the accumulation of
mutant nuclear loricrin may influence a host of cell processes
that lead to enhanced cell proliferation.
In the present study, we describe mice that express tetra-
cycline-inducible dominant-negative c-jun (TAM67) in the
suprabasal murine epidermis. Dominant-negative c-jun
dimerizes with all jun/fos factors to inhibit transcription
(Brown et al., 1994). Jun/fos factors are key controllers of
keratinocyte proliferation and differentiation (Efimova et al.,
1998; Efimova and Eckert, 2000; Efimova et al., 2002, 2003;
Eckert et al., 2004). Remarkably, these mice develop an
authentic loricrin keratoderma-like phenotype. Moreover,
studies in loricrin-null background suggest that loricrin is not
required for this response. On the basis of these findings, we
suggest that reduced suprabasal AP1 factor signaling in the
suprabasal epidermis is sufficient to cause keratoderma, and
that suppressed suprabasal epidermal AP1 factor function may
be involved in a range of keratoderma types.
RESULTS
TAM67 in suprabasal epidermis
SKH1-TAM67-rTA mice are engineered to encode the TetO-
TAM67-FLAG and hINV-rTA gene expression cassettes. The
hINV-rTA construct uses the human involucrin promoter to
target expression of the rTA to the suprabasal epidermis.
Doxycycline binding produces an active form of rTA, which
binds to TetO to drive suprabasal expression of TAM67-FLAG.
TAM67 forms inactive heterodimers with other AP1 factors,
which interact with AP1 response elements in a normal
manner but do not activate transcription. This results in
reduced expression of AP1-responsive genes (Han et al.,
2012). As an initial step in characterization of the role of
TAM67-FLAG in the epidermis, we confirmed that TAM67-
FLAG interacts with AP1 response elements and reduces
expression of AP1 target genes. TAM67-rTA mice were
treated for 3 days with or without doxycycline, and nuclear
epidermal extracts were prepared. Figure 1a shows an
increase in the quantity of shifted AP1c-P32 probe in extract
prepared from TAM67-expressing epidermis, and that this
binding is reduced by addition of excess radioinert AP1c. In
addition, direct TAM67-FLAG binding to AP1c-P32 was con-
firmed by anti-FLAG supershift (Figure 1a). Expression of
TAM67 in this tissue is expected to reduce expression of
AP1 factor–regulated genes. To assess this, we monitored the
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Figure 1. TAM67-FLAG interacts with AP1 response element and suppresses
AP1-responsive genes. SKH1-TAM67-rTA mice were treated with (þ ) or
without ( ) 2 mg ml 1 doxycycline in drinking water for 3 days.
(a) Interaction of TAM67 with AP1 site consensus element. Epidermis from
control and TAM67-expressing epidermis were collected by high-temperature
separation (Rorke et al., 2010), and nuclear extracts were prepared and
incubated with AP1c-P32 as indicated. NE, nuclear extract. The arrow indicates
migration of the mobility shifted bands, and the arrow/asterisk indicates
migration of the supershifted band (anti-FLAG-treated sample). A 40-fold
excess of AP1c was added as indicated to demonstrate binding specificity.
(b) Murine epidermis was collected free of the dermis by high-temperature
separation as previously described (Rorke et al., 2010). Total extract was
prepared for immunoblot to detect the indicated proteins. TAM67-FLAG was
detected with anti-FLAG. Similar results were observed in each of the three
experiments.
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expression of involucrin and loricrin, two genes that require
AP1 transcription factors for expression (Yoneda et al., 1992;
Jang and Steinert, 2002; Eckert et al., 2004). TAM67-rTA mice
were treated with or without 2 mg ml 1 doxycycline for 3
days, and total epidermal extracts were assayed for involucrin
and loricrin. We find that both involucrin and loricrin levels
are reduced in TAM67-expressing epidermis (Figure 1b),
thereby providing biochemical evidence for a TAM67 impact
on the tissue.
The phenotype of SKH1-TAM67-rTA mice
To characterize the phenotype of SKH1-TAM67-rTA mice,
littermates were treated with or without 2 mg ml 1 doxycy-
cline in drinking water for 0–21 days. The SKH1 genetic
background was used, as the hairless phenotype permits
enhanced visualization of the phenotype. However, it is
important to note that the mice are completely immune
competent. Figure 2a shows that TAM67-FLAG expression is
associated with the development of a honeycomb epidermal
phenotype that is evident during the first week and that this
phenotype progresses such that the mice develop extensive
hyperkeratosis by 21 days. Figure 2b shows a closer view of
the 21 day doxycycline-treated mouse, illustrating the exten-
sive hyperkeratosis and fissures that develop at the back of the
animal, and Figure 2c shows the hyperkeratosis that develops
at the bottom of the feet and the unusual ‘‘club’’ appearance
of the nails. The toes also display a tendency toward
pseudoainhum at the junction between the foot and digits.
We next examined epidermal histology. Figure 2d shows the
thin epidermis and normal keratinization characteristic of
control mice, whereas Figure 2e shows the extensive hyper-
keratosis observed in the epidermis of doxycycline-treated
mice. Figure 2f shows the extensive parakeratosis (nuclei
retention, arrows) in dead cells of the cornified layer.
As mutant loricrin redistributes from the cell periphery to
the nucleus in human keratoderma, we examined the tissue
and subcellular distribution of murine loricrin in the TAM67-
expressing mice (Ishida-Yamamoto et al., 1998a; Ishida-
Yamamoto, 2003). Figure 2g shows a thin margin of loricrin
staining in the epidermal cornified layer of control mice.
Much to our surprise wild-type loricrin redistributes to the
nucleus in the suprabasal epidermis of TAM67-FLAG-expres-
sing mice (Figure 2h). Figure 2i shows sections co-stained with
anti-loricrin and 40 6-diamidino-2-phenylindole, which con-
firms nuclear loricrin localization in suprabasal cells. Figure 2j
shows that doxycycline treatment results in expression of
TAM67-FLAG and confirms the complete lack of expression
in the absence of doxycycline. These studies show that SKH1
mice expressing TAM67 in the suprabasal epidermis develop a
phenotype that includes progressive epidermal hyperkeratosis,
which is associated with parakeratosis, hyperkeratosis of the
skin and base of the feet, and nuclear accumulation of loricrin.
This phenotype closely resembles features of human kerato-
derma (Camisa and Rossana, 1984; Schmuth et al., 2004).
Rapid onset of phenotype
We next studied the time course of phenotype onset in order
to understand the sequence of events during disease
development. SKH1-TAM67-rTA mice were treated with
doxycycline, and the epidermis was harvested at 0, 12, 24,
48, and 72 hours after initiation of treatment. Figure 3a shows
initial evidence of nuclear TAM67-FLAG accumulation in
epidermal suprabasal cells at 12 hours with continued accu-
mulation at subsequent times (arrows). TAM67-FLAG level, as
measured by immunoblot, is maximal by 48 hours and is
maintained thereafter (not shown). Figure 3a shows that no
TAM67-FLAG is detected in the nuclei of basal cells. To
determine the time of initiation of epidermal cell hyperproli-
feration, we monitored the Ki67 level. Figure 3b shows
increased Ki67 staining that is evident at 48 and 72 hours
and is associated with increased epidermal thickness as
detected in hematoxylin and eosin sections (Figure 3a). We
also monitored loricrin subcellular distribution during this time
course (Figure 3b). At time zero, loricrin is present as a thin
band in the cornified layer, but at 24, 48, and 72 hours after
activation of TAM67-FLAG expression loricrin assumes a
punctate intracellular localization (Figure 3b).
We examined loricrin and TAM67-FLAG localization in
detail by co-staining sections with anti-loricrin (red) and anti-
TAM67-FLAG (green). At time zero, loricrin is detected as part
of the cornified envelope (red) and, as expected, no TAM67-
FLAG (green) is detected (Figure 4). At 12 hours after initiation
of doxycycline treatment, TAM67-FLAG is detected in the
nuclei, whereas loricrin remains associated with the cornified
envelope. However, by 24 hours there is clear evidence for
redistribution of loricrin into some nuclei in the suprabasal
layer (red). Moreover, this accumulation is maintained at 48
and 72 hours (Figure 4) and at 14 days (Figure 2h and i). These
findings indicate that nuclear loricrin accumulation is an early
event in phenotype development and that nuclear accumula-
tion is sustained thereafter. It is interesting to note that loricrin
is present in nuclei that are strongly and weakly TAM67-FLAG
positive (Figure 4), suggesting that TAM67-FLAG does not
directly act to move loricrin to the nucleus. We speculate that
loricrin may be moved to the nucleus via carrier protein–
dependent transport, but this remains to be determined.
Pseudoainhum
Pseudoainhum (constriction) and autoamputation of the digits
is a signature phenotype of loricrin keratoderma patients and
is also observed in mutant loricrin-expressing mice (Ishida-
Yamamoto et al., 1997; Suga et al., 2000). As shown in
Figure 5, TAM67-expressing mice develop a severe pseu-
doainhum response. Constriction bands accumulate on the tail
and are particularly evident after removal of doxycycline
when the phenotype is permitted to normalize. The mouse
in Figure 5 was treated with doxycycline for 21 days followed
by removal of doxycycline. The photographs (Figure 5a and b)
were taken at 7 and 11 days after doxycycline removal. This
shows that the accumulated scale is lost with the loss of
TAM67 expression, indicating that the phenotype is reversible
(Figure 5a) with some residual scarring that slowly normalizes
(Figure 5b). Figure 5c and d shows the tails of two mice at 11
days after removal of doxycycline treatment. The arrows
indicate some of the restriction bands on the tail. A significant
number of mice lose all or a portion of the tail. Figure 5e
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confirms that removal of doxycycline results in loss of TAM67-
FLAG expression. Pseudoainhum is also observed on the
digits. Figure 5f is an image showing development of edema
in a digit undergoing pseudoainhum. This phenotype mimics
the human disease (Seirafi et al., 2011).
Role of loricrin
An interesting and unexpected observation is the nuclear
accumulation of wild-type loricrin in epidermal keratinocytes
in TAM67-expressing mice (Figure 2i). This begs the question
of whether nuclear accumulation of wild-type loricrin is
required for keratoderma phenotype development in this
model. To assess this, we examined the impact of TAM67
expression in SKH1-TAM67-rTA mice that are homozygous,
heterozygous, and null for loricrin. Mice were treated for 21
days with doxycycline prior to tissue harvest. Figure 6a
confirms the TAM67 and loricrin expression status of the mice
and shows that doxycycline treatment activates TAM67-FLAG
expression at comparable levels in each strain. We next
examined the impact of loricrin loss on the TAM67-dependent
7 days
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Figure 2. Characterization of SKH1-TAM67-rTA mice. SKH1-TAM67-rTA mice were administered drinking water supplemented with or not supplemented with
2 mg ml 1 doxycycline. (a) Doxycycline-treated and untreated littermates were photographed at 7, 14, and 21 days. (b,c) Enlarged images showing
hyperkeratinization of the dorsal epidermis and foot in mice treated for 21 days with doxycycline. Panel b includes an image of an untreated littermate.
(d) Histological appearance of the epidermis from an untreated littermate. (e) Histological appearance of the epidermis from a 14 day doxycycline-treated
littermate. The line labeled ‘‘E’’ marks the extent of the living epidermis. (f) Histological appearance of the cornified layer from e shows incomplete
nuclear destruction (parakeratosis) in the cornified layer. The arrows indicate nuclei. (g,h) Loricrin distribution in untreated and 14 day doxycycline-treated
SKH1-TAM67-rTA mice. The dotted lines indicate the dermal/epidermal junction. (i) Co-staining with 40 6-diamidino-2-phenylindole (DAPI; nuclear) and
anti-loricrin confirms loricrin nuclear distribution in the epidermis from a 14 day doxycycline-treated mouse. The scale bar ¼ 20mm. (j) Immunoblot shows
accumulation of TAM67-FLAG in a 14 day doxycycline-treated mouse and the absence of expression in an untreated littermate.
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phenotype. Hematoxylin and eosin staining shows that TAM67
expression induces an epidermal hyperproliferative phenotype
in the presence and absence of loricrin and that this is
associated with activation of expression of the hyperprolifera-
tion-associated keratin, K6 (Figure 6b). As a control, we show
that suprabasal expression of keratin 1 is maintained (Figure 6b).
However, the most striking observation is that the epidermal
scaling keratoderma-like phenotype develops unabated in mice
with reduced or absent loricrin (Figure 6b and 6c).
DISCUSSION
Keratodermas are a group of diseases characterized by
thickening of the epidermis associated with marked hyper-
plasia and hyperkeratosis (Christiano, 1997). In the course of
studies designed to understand AP1 transcription factor
function in epidermis, we produced mice in which AP1
transcription factor function is inactivated in the suprabasal
epidermis (Rorke et al., 2010). In this model, we induce
suprabasal epidermal expression of TAM67, a dominant-
negative form of c-jun that inhibits AP1 factor function,
using a doxycycline-inducible system. TAM67 dimerizes
with and inhibits transcriptional activation potential of all
AP1 factors. We show that TAM67-FLAG interacts with AP1
response elements in a competitive manner and that this is
associated with reduced expression of representative AP1
factor responsive genes. A remarkable finding is that these
mice display a phenotype that includes all of the hallmarks of
keratoderma. As AP1 factor inactivation in the basal epidermis
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Figure 3. Time course of impact of TAM67-FLAG on epidermal end points. SKH1-TAM67-rTA mice were administered 2 mg ml 1 doxycycline in drinking water,
and at the indicated times tissue was harvested for characterization. (a) Epidermal morphology (hematoxylin and eosin (H&E) stain) and immunodetection of
TAM67-FLAG using a peroxidase-based antibody. The arrows indicate nuclear TAM67-FLAG accumulation in cells of the suprabasal epidermis. (b)
Immunodetection of Ki67 and loricrin. Ki67 is detected in the basal and immediately suprabasal cell layers in TAM67-FLAG-expressing mice. Loricrin shifts from
staining the margin of the cornified layer at 0 and 12 hours to staining of nuclei at 24, 48, and 72 hours. Scale bars ¼ 50mm.
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produces no such phenotype (Young et al., 1999, 2002;
Cooper et al., 2003), this implies that epidermal compart-
ment–specific changes in transcription factor signaling can
cause keratoderma pathogenesis. Early changes include a
progressive increase in skin thickness at 48 to 72 hours after
TAM67 expression, and a parallel increase in cell prolifera-
tion. This is associated with nuclear accumulation of wild-type
loricrin and changes in expression of differentiation markers.
On a longer time scale, beginning after several days, the mice
develop a honeycomb epidermal appearance. This is followed
by accumulation of a thick layer of epidermal cornified
material and tail and digit pseudoainhum and autoamputation.
The fact that this phenotype so closely mimics human
keratoderma strongly suggests that suppression of AP1 factor
signaling is an important event in disease development.
Keratoderma includes both inherited and acquired forms.
Inherited forms of this disease are associated with mutations in
structural proteins (keratins), cornified envelope–associated
proteins (loricrin, transglutaminase), cohesion proteins (des-
moglein 1, plakophilin, desmoplakin), proteins of cell-to-cell
communication (connexins), and transmembrane proteins
(cathepsin C) (Christiano, 1997; Kimyai-Asadi et al., 2002;
Amagai and Stanley, 2012). Most of these mutations are
autosomal dominant, although some are recessive (Kimyai-
Asadi et al., 2002). The Vohwinkel syndrome and the Camisa
variant of Vohwinkel syndrome are highly debilitating forms of
the disease that display pseudoainhum and autoamputation of
the digits and other extremities. Connexin mutations have
been identified in Vohwinkel syndrome (Scott et al., 2012),
and targeted expression of mutant connexin in the suprabasal
epidermis in mice produces a keratoderma-like phenotype
(Schmuth et al., 2004). A mutation in the loricrin gene, which
leads to nuclear accumulation of loricrin, is associated with
the Carmisa variant of Vohwinkel syndrome (Suga et al.,
2000). In addition, some forms of keratoderma are acquired in
response to treatment with drugs, exposure to chemicals,
malnutrition, infection, or response to cancer (Patel et al.,
2007). However, the underlying mechanisms that drive these
diseases are not well understood. In particular, knowledge of
changes in cell signaling is limited.
AP1 factors and keratoderma
AP1 transcription factors (c-jun, junB, junD, c-fos, Fra-1, and
Fra-2) are important controllers of keratinocyte differentiation.
They control differentiation and proliferation and are fre-
quently perturbed in disease processes (Crish et al., 1993;
Welter et al., 1995; Eckert et al., 1997, 2004; Efimova et al.,
2003, 2004; Gerdes et al., 2006). A role for transcription
LORICRIN LORICRIN
TAM67-FLAG TAM67-FLAG
LORICRIN
TAM67-FLAG
+Dox (72 hours)
LORICRIN
TAM67-FLAG
LORICRIN
TAM67-FLAG
+Dox (48 hours)
+Dox (12 hours)
+Dox (0 hours) +Dox (24 hours)
Figure 4. Staining of loricrin (red) and TAM67-FLAG (green) showing that TAM67-FLAG appears in the nucleus at 12hours and loricrin appears in the nucleus
beginning at 24hours. Red arrows indicate loricrin localization, green arrows indicate TAM67-FLAG localization, and yellow signal indicates co-localization.
TAM67-FLAG and loricrin co-localize in many but not all suprabasal nuclei.
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factors in the development of keratoderma has not been
studied. The present study shows that direct suppression of
AP1 transcription factor function can produce a keratoderma
phenotype. It is interesting that the phenotype is observed in
the absence of mutation in proteins known to be mutated in
keratoderma, and that the phenotype is only observed when
AP1 factor function is selectively inactivated in the suprabasal
epidermis. Suprabasal AP1 factor inactivation appears to
inhibit/delay normal keratinocyte differentiation and also
cause an increase in basal layer proliferation. The latter
suggests a potential indirect effect due to incomplete
differentiation and may involve paracrine mediators. Given
the central role that AP1 factors have in regulating
keratinocyte function, it is perhaps not surprising that
reducing AP1 factor signaling produces a keratoderma
phenotype. It is interesting to speculate that suppressed AP1
factor function may be an underlying response that is common
in a range of keratoderma types––both genetically inherited
and acquired.
Role of loricrin
An interesting property of the mice produced in the present
study is the presence of two signature features commonly
associated with the Camisa variant of Vohwinkel syndrome
(loricrin keratoderma). These are nuclear loricrin accumula-
tion and pseudoainhum/autoamputation. Loricrin keratoderma
is an interesting form of the disease that is characterized by
honeycomb-like palmoplantar keratoderma, hyperkeratosis,
tissue buildup on the dorsal hands and feet, nuclear accumu-
lation of mutant loricrin, and pseudoainhum and autoamputa-
tion of extremities. Loricrin is a structural protein that is a
component of the cornified envelope (Mehrel et al., 1990;
Candi et al., 2005). In normal epidermis, it is produced during
the terminal stages of differentiation and is then crosslinked as
part of the cornified envelope (Mehrel et al., 1990; Hohl et al.,
1991). In keratoderma, mutant loricrin accumulates in the
nucleus due to a frameshift mutation that adds a nuclear
localization signal at the c-terminal end of the protein
(Maestrini et al., 1996; Korge et al., 1997; Takahashi et al.,
1999; Matsumoto et al., 2001; O’Driscoll et al., 2002;
Gedicke et al., 2006; Drera et al., 2008). However, what
loricrin does in the nucleus is not known. Although wild-type
loricrin is not thought to cause disease, our observation of its
accumulation in the nucleus at early times (12 to 24 hours)
during phenotype development suggests that it could be
driving the phenotype. Moreover, some investigators have
described nuclear localization of wild-type loricrin (Ishida-
Yamamoto et al., 1993; Yoneda et al., 2010a, b). We do not
know why wild-type loricrin accumulates in the nucleus in the
presence of TAM67, but we presume that unknown factors are
produced that facilitate this movement. To determine whether
wild-type loricrin has a role in disease development, we
studied phenotype development in a loricrin-null
background. These studies clearly indicate that a complete
phenotype develops in the absence of loricrin, indicating that
wild-type loricrin has no role. Thus, suprabasal AP1 factor
inactivation is sufficient to drive the phenotype.
Pseudoainhum
Pseudoainhum and autoamputation is associated with the
Vohwinkel syndrome and the Camisa Vohwinkel syndrome
variant (Camisa and Rossana, 1984; Korge et al., 1997;
Maestrini et al., 1999; Schmuth et al., 2004). In our model,
(7 days) (11 days)
(11 days)
(11 days)
+Dox (21 d)
+Dox (21 d) –Dox (7 d)
TAM67-FLAG
β-Actin
Total lysate
20
45
+
+
Figure 5. Pseudoainhum (autoamputation) in TAM67-expressing mice.
SKH1-TAM67-rTA mice were treated for 21 days with 2 mg ml1 doxycycline,
and the doxycycline was then removed for 7 or 11 days. (a,b) Appearance of
mice at 7 and 11 days after discontinuation of doxycycline treatment. The
accumulated cornified material is progressively shed from the skin surface.
The arrows indicate the remaining cornified material and a residual scar.
(c,d) Appearance of the tails of two mice after 21 day doxycycline treatment
followed by 11 days without doxycycline. The arrows show representative
pseudoainhum bands on each tail. In some mice the tail is lost because of
autoamputation. (e) An immunoblot showing TAM67-FLAG level in 21
day doxycycline treatment mice versus mice treated for 21 days followed
by 7 days of discontinued treatment. (f) Early-stage pseudoainhum of digits in
mouse treated for 21 days with doxycycline. The arrow indicates
pseudoainhum-associated edema.
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suprabasal AP1 factor inactivation produces digit and tail
pseudoainhum and autoamputation. The phenotype is
particularly evident on the tail. This is a complex aspect of
keratoderma that is not well understood (Rashid et al., 2007).
The disease is thought to involve a complex series of events
that include abnormal vascular ligation, secondary atrophy
and fibrosis, and constriction leading to autoamputation
(Rashid et al., 2007). It also may involve genetic or systemic
components, as the response is often symmetric and bilateral
(Rashid et al., 2007). It is particularly interesting that
compromised suprabasal AP1 factor function may trigger a
series of events that drive this phenomenon.
The fact that the phenotype is inducible and reversible
in our model suggests that it will be possible to study
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Figure 6. Suppression of suprabasal AP1 factor signaling is sufficient for phenotype development; –loricrin is not required. (a) Immunoblot confirmation of
mouse genotype. SKH1 mice of the indicated TAM67-FLAG and loricrin genotypes were treated for 21 days with (þ ) or without ( ) 2 mg ml1 doxycycline. At
21 days epidermal extracts were prepared for detection of the indicated proteins. (b) Hematoxylin and eosin, K1, and K6 staining of epidermis from 21 day
doxycycline-treated mice. Arrows or dotted lines indicate the epidermal/dermal junction. Scale bars ¼ 50mm. (c) Appearance of mice of the indicated genotype
after 21 days of doxycycline treatment. Absence of loricrin did not prevent phenotype development. (d) Hypothesis: inhibition of suprabasal AP1 factor signaling
produces a keratoderma-like phenotype that closely resembles human keratoderma by altering gene expression.
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pseudoainhum and autoamputation development and regres-
sion. On the basis of these findings, we propose that reduced
AP1 transcription factor function in the suprabasal epidermis
leads to presently unknown changes in gene expression that
drives the keratoderma phenotype (Figure 6d). We further
propose that changes in AP1 factor signaling may be a
common event in multiple keratoderma types and may be
involved in the pathogenesis of acquired keratoderma that
develops in response to environmental factors.
MATERIALS AND METHODS
SKH1-TAM67-rTA mice
TAM67 is a dominant-negative form of c-jun that lacks the c-jun
amino terminus (Brown et al., 1994). TAM67 forms complexes with
all jun and fos transcription factors, but when these complexes
interact with DNA response elements they fail to activate
transcription (Brown et al., 1994). Thus, it can be used to create an
AP1 factor function–deficient environment. We cloned TAM67-FLAG
into pTRE-Tight to produce pTRE-Tight-TAM67-FLAG. The TetO-
TAM67-FLAG-SV40 transcription cassette from this plasmid was
microinjected into B6SJL embryos (Rorke et al., 2010) to produce
TetO-TAM67-FLAGTG/ (strain 44) mice. A FLAG epitope was
included at the carboxyl terminus of TAM67 to facilitate TAM67
detection. These mice were mated with FVB hINV-rTATG/ mice
(Jaubert et al., 2004) to produce bi-transgenic B6SJL/FVB TAM67-
FLAGTG/ /hINV-rTATG/ mice (TAM67-rTA) (Rorke et al., 2010).
In the present studies, we transferred the TetO-TAM67-FLAG and
hINV-rTA genes to the SKH1 genetic background by breeding for five
generations. These mice were then bred to produce SKH1-TAM67-
rTA mice. Treatment of these mice with doxycycline results in
TAM67-FLAG expression in the suprabasal layers. This is due to
involucrin promoter–specific targeting of rTA to these layers (Rorke
et al., 2010). The mice were genotyped using DNA-dependent PCR
and primers that detect each transgene (Rorke et al., 2010). The SKH1
genetic background was utilized in these studies because the mice are
hairless, and this facilitates visualization of the epidermis. SKH1 mice
are immune competent. Loricrin knockout mice (Koch et al., 2000)
were bred for five generations into the SKH1 background. The
wild-type and loricrin knockout genotypes were detected using
50-CACTCCCAGCACAATAAGAA-30 and 50-TTGCATCGCATTGTCT
GAGT-30, respectively, as the forward primers. The reverse primer
was 50-GCACTGGGAGAGTGGTAAGC-30 for both wild-type and
knockout mice. The primers produce bands at B350 (knockout)
and 650 (wild type) nucleotides. The mice were housed in the
University of Maryland School of Medicine animal facility in
compliance with the NIH regulations.
Antibodies and immunological methods
Immunofluorescence was performed using paraffin-embedded for-
malin-fixed sections as previously described (Crish et al., 1998, 2002,
2006). Loricrin (PRB-145P), K1 and K6 antibodies were from Covance
(Emeryville, CA). Ki67 (TEC-3) antibody was from Dako (Cupertino,
CA), and b-actin (A5441) and FLAG (M2) (F4049)-specific antibodies
were obtained from Sigma (St Louis, MO). Primary antibody
localization was visualized using an appropriate fluorophore-
conjugated secondary antibody. For immunoblot, the epidermis was
separated from the dermis, frozen in liquid nitrogen, pulverized, and
then suspended in dye-free Laemmli sample buffer. The suspension
was sonicated, particulates were removed by centrifugation, and
soluble extract was electrophoresed on a polyacrylamide gel and
transferred to nitrocellulose for immunoblot (Crish et al., 1998, 2002,
2006). Unless otherwise indicated, the experiments were repeated
three separate times, and sections and extracts were monitored from
the epidermis of three mice per treatment group.
Gel mobility shift assay
Epidermis was isolated for preparation of nuclear extract using NE-
PER Nuclear and Cytoplasmic Extraction Reagent (78833, Pierce
Biotechnology, Rockford, IL). TAM67-FLAG binding to double-
stranded AP1 consensus (AP1c) oligonucleotide 50-CGCTTGAT-
GAGTCAGCCGGAA-30 (E320A, Promega, Madison, WI, AP1 site in
bold) was monitored by gel mobility shift assay. Three micrograms of
nuclear extract were incubated for 30 minutes at room temperature in
a volume of 20ml containing 20 mM HEPES, pH 7.5, 10% glycerol,
50 mM KCl, 2 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 1mg ml
 1
poly(dI:dC), 0.1 mg ml 1 bovine serum albumin, and 40,000 c.p.m.
radioactive double-stranded AP1c-P32 or AP1-5-P32 oligonucleotide.
For competition studies, a fixed (40-fold) molar excess of nonradioac-
tive AP1c competitor oligonucleotide was added to the DNA binding
reaction. For the gel mobility supershift assay, 2mg of antibody
specific for FLAG (F3165, Sigma) was added to the reaction mixture
and incubated for 1 hour at 25 1C. The 32P-labeled probe was then
added, and the incubation was continued for an additional 30 min-
utes at 25 1C. Protein-DNA complexes were resolved in 6% poly-
acrylamide gels under nondenaturing conditions (Adhikary et al.,
2004, 2005).
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